Register Login
Register to leave comments
  • News bot June 17, 2026, 8:16 p.m.

    📋 APREA THERAPEUTICS, INC. (APRE) - Regulatory Update

    Filing Date: 2026-06-17

    Accepted: 2026-06-17 16:15:28

    Event Type: Regulatory Update

    Event Details:

    APREA THERAPEUTICS, INC. (APRE) Announces Regulatory Update APREA THERAPEUTICS, INC. (APRE) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (APREA THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Decitabine Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    ATRN-119 Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Stereotactic Body Radiation Therapy (SBRT) Drug Phase PHASE1 HPV Positive Oropharyngeal Squamous Cell Carcinoma ClinicalTrials.gov
    Dabrafenib Other Phase PHASE1 Melanoma ClinicalTrials.gov
    APR-246 Other Phase PHASE1 Melanoma ClinicalTrials.gov
    Azacitidine Other Phase PHASE1 Myelodysplastic Syndrome With Gene Mutation ClinicalTrials.gov
    APR-548 + Azacitidine Other Phase PHASE1 MDS ClinicalTrials.gov
    APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT Other Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT Other Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL Other Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    APR-246 (eprenetapopt) + Acalabrutinib in CLL Other Phase PHASE1 Non Hodgkin Lymphoma ClinicalTrials.gov
    Venetoclax Other Phase PHASE1 Myeloid Malignancy ClinicalTrials.gov
    Pegylated Liposomal Doxorubicin Hydrochloride (PLD) Other Phase PHASE2 High-grade Serous Ovarian Cancer ClinicalTrials.gov
    Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) Other Phase PHASE1 Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 ClinicalTrials.gov
    APR-246 + azacitidine Other Phase PHASE3 MDS ClinicalTrials.gov
    APR-246 (eprenetapopt) + Pembrolizumab Other Phase PHASE1 Bladder Cancer ClinicalTrials.gov
    APR-1051 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: APREA THERAPEUTICS, INC.
    • Ticker Symbol: APRE

Search

News categories